All content for touchPODCAST is the property of touchpodcast and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Overcoming EGFR-TKI resistance: Emerging therapies and biomarker strategies in NSCLC
touchPODCAST
30 minutes
1 month ago
Overcoming EGFR-TKI resistance: Emerging therapies and biomarker strategies in NSCLC
Module 1: Beyond EGFR: Addressing actionable drug resistance mechanisms
touchCLINICAL PERSPECTIVES for touchONCOLOGY and touchRESPIRATORY
In this module, Professors Jänne and Girard explore the challenges of resistance to EGFR-targeted therapies in non-small cell lung cancer. They discuss how mechanisms such as MET and HER2 amplification drive resistance to first-line osimertinib, review emerging targeted strategies to overcome these barriers, and highlight the importance of biomarker testing and managing treatment side effects when shaping second-line options for patients.
Course director
Prof. Pasi Jänne, Dana-Farber Cancer Institute, Boston, MA, USA
The clinical expert
Prof. Nicholas Girard, Institut Curie, Paris, France
This touchPODCAST is for HCPs only.
This activity is funded by an educational grant from AstraZeneca Ltd.
This medical education is jointly provided by USF Health and touchIME.
touchIME is an EBAC® accredited provider.
For further information visit our website:
add url
